Background and Purpose-The Stroke-Thrombolytic Predictive Instrument (Stroke-TPI) uses multivariate equations to predict outcomes with and without thrombolysis. We sought to examine whether such a multivariate predictive instrument might be useful in selecting patients with a favorable risk-benefit treatment profile for therapy after 3 hours. Methods-We explored outcomes in patients from 5 major randomized clinical trials testing intravenous recombinant tissue plasminogen activator (rt-PA) classified by the Stroke-TPI as "treatment-favorable" or "treatment-unfavorable." We used iterative bootstrap re-sampling to estimate how such a model would perform on independent test data. Results-Among patients treated within the 3-to 6-hour window, 67% of patients were classified by Stroke-TPI predicted outcomes as "treatment-favorable" and 33% were classified as "treatment- 
C linical trials including patients beyond the 3-hour timewindow have failed to find overall benefit for intravenous recombinant tissue plasminogen activator (rt-PA) in acute stroke, [1] [2] [3] [4] although joint analysis of all randomized data strongly suggests that beneficial effects extend beyond 3 hours. 5 However, treatment beyond 3 hours has not been approved by regulatory agencies or endorsed in most guidelines. 6 The narrow time-window contributes to the low rate of thrombolysis. 7, 8 Previously, we found evidence suggesting the absence of benefit in these trials with patients enrolled beyond 3 hours from symptom onset may obscure treatment-favorable and treatment-unfavorable patients identifiable on the basis of pretreatment clinical characteristics. 9 We recently developed a predictive instrument for thrombolysis in stroke (the StrokeThrombolytic Predictive Instrument [Stroke-TPI]), which predicts outcomes with and without thrombolysis. 10 This study's purpose was to test whether such a prognostic instrument might be useful for the selection of patients with a favorable risk-benefit profile for IV rt-PA when treated after 3 hours of stroke onset.
Methods

Overview of Analysis Design
Having developed the Stroke-TPI on a combined database of randomized clinical trials ( 10 we examined whether it might be able to select treatment-favorable patients who come for treatment after 3 hours and are thereby currently ineligible for rt-PA. We used the Stroke-TPI to classify patients in the combined database into "treatment-favorable" or "treatment-unfavorable" patients based on whether they were more likely to have a normal or near-normal outcome with or without rt-PA. We examined the characteristics, outcomes, and the treatment effects in these groups.
Because the Stroke-TPI was developed on the combined database used for this analysis, these results are likely to be overly optimistic and might represent the upper limit of model performance. Therefore, we investigated how such a model would perform on independent data. Figure 1 summarizes our approach. First, the combined database was divided into derivation and test subsets. To select the derivation subset, we randomly sampled patients from the combined database with replacement (ie, bootstrap sampling), to reconstitute a derivation database that was the same size as the overall combined database ("0.632 bootstrapping"). 11 Because patients are sampled with replacement, some patients are drawn repeatedly and some (Ϸ37% on average) are excluded. The excluded portion forms the independent test dataset. Stepwise logistic regression was used on the derivation dataset to develop a model predicting the probability of a normal or near-normal outcome (modified Rankin Scale [mRS] score Յ1), with and without rt-PA, as with the development of the Stroke-TPI. 10 The model was then applied to those patients treated after 3 hours in the independent test data, to classify them as "treatment-favorable" or "treatment-unfavorable," based on model predictions. We then examined the actual outcomes in these patients, hypothesizing that "treatment-unfavorable" patients would do worse with rt-PA than with placebo, whereas "treatmentfavorable" patients would benefit from rt-PA.
Because the 3-to 6-hour subset of the test dataset is not large enough to make reliable treatment-effect estimates in each of the favorable/unfavorable subgroups, and because any given sample might be nonrepresentative, we iterated the bootstrap sampling and modeling procedures 250 times. Each iteration produced a different derivation dataset, a different model (with different variables and coefficients) and a different test dataset. Through this iterative bootstrap sampling, modeling, and testing, we arrived at a stable estimate of the decrement in the degree of benefit in the test dataset compared with the derivation dataset, and also of the "gain" in the degree of benefit expected with the use of such a multivariable model in independent data compared with the conventional selection criteria.
Outcomes
Our primary outcome was the degree of benefit among modelselected "treatment-favorable" patients in the test set across samples, compared with that seen overall in the 3-to 6-hour sample from which the subgroup was drawn, using the mRS Յ1 outcome. In addition, as a secondary outcome, we examined the proportion of patients who were dead or severely disabled (mRS Ն5), by treat ment-assignment, in the treatment-favorable and treatment-unfavorable groups.
Results
Overall, among patients treated between 3 and 6 hours of symptom onset, there was no significant difference in good outcomes between the treated and untreated groups at 90 days (40% in rt-PA-treated patients; 38% in control patients, Pϭ0.51). When the Stroke-TPI model was applied to the overall database on which it was developed, the treatmentfavorable group comprised 67% of the sample and demonstrated an absolute margin of benefit from rt-PA of 9.8% (mRS Յ1: 44.0% with rt-PA versus 34.2 with placebo; PϽ0.005). Outcomes in the 33% classified as treatmentunfavorable showed harm with rt-PA (mRS Յ1ϭ31.3% versus 38.3% with placebo; PϽ0.004). The interaction for the treatment-effect between the groups was highly significant (PϽ0.0001). Table 1 shows the characteristics of patients classified as treatment-favorable versus treatment unfavorable, according to the Stroke-TPI. There was significant overlap in the value of individual variables that modify rt-PA effect, indicating that a combination of factors needs to be examined simultaneously, as by a multivariable model. The outcomes shown in Table 1 indicate that, though the model was developed to predict a normal or near-normal outcome (mRS Յ1), patients likely to benefit on this outcome also benefitted from thrombolysis across other measures.
Characteristics of High-Benefit Versus Low-Benefit Patients
Iterative Bootstrap Resampling, Modeling and Testing
Across the 250 sampling iterations, each derivation dataset had 2131 patients; each test dataset had on average 784 Figure 1 . Methods overview. This figure illustrates the overall approach to estimating model performance on an independent data sample. After developing a combined database, a derivation subset was randomly selected by (bootstrap sampling). A model was derived on this derivation subset, (1) using an automated stepwise selection modeling procedure. Given our sampling technique, Ϸ37% of patients from the overall data set were excluded from the derivation subset; these patients comprised the test subset. The model was then applied to the 3-to 6-hour subgroup of the test subset, and (2) to classify that subset into "treatment-unfavorable" and "treatment-favorable" patients, based on model predictions. Actual outcomes were then examined in these subgroups across treatment (rt-PA vs placebo). This process (steps 1 through 3) was repeated 250 times, and we report the average outcomes across all sets.
patients. Table 2 shows the variables tested and the proportion of the 250 models into which they were selected.
When the models were applied directly to the dataset on which they were developed (Figure 2 ), on average, 33% (interquartile range [IQR], 27% to 39%) of patients were classified as "treatment-unfavorable," and 67% (IQR, 61% to 72%) were classified as "treatment-favorable." As predicted, patients in the treatment-unfavorable group, on average, had worse outcomes with rt-PA than with placebo, by an absolute margin of 10.2% (IQR, 6.9% to 14.2%), whereas patients in the treatment-favorable group, on average, had better outcomes with rt-PA than with placebo, by an absolute margin of 8.1% (IQR, 5.8% to 10.7%). When the models are applied to the test datasets (Figure 2 ), on average, 33% (IQR, 26% to 40%) of patients were classified as "treatment-unfavorable" and 67% (IQR, 61% to 73%) of patients were classified as "treatment-favorable." Within the treatment-unfavorable group, again, outcomes were worse with rt-PA treatment than with placebo, whereas in the treatment-favorable group, on average, outcomes were better with rt-PA therapy. As expected, there was some "shrinkage" of the absolute margin benefit in the "treatment-favorable" group on the test datasets compared with the derivation datasets, but 64% of the margin of benefit was maintained, with an average absolute margin of 5.2% on average (IQR, 1.7% to 8.6%). This compares favorably to the overall 1.8% (IQR, Ϫ0.5 to 4.1) average treatment benefit in the 3-to 6-hour window in the test datasets from which these patients were selected (PϽ0.0001 for the difference in benefit between these 2 samples in the test datasets). If the benefit found using the Stroke-TPI has a similar degree of "shrinkage" when tested on independent data, than the margin of absolute benefit in the treatmentfavorable subgroup (9.8% in the combined database) would be expected to be 6.3%.
Death or Severe Disability
We also examined the likelihood of severe disability or death (mRS Ն5) in patients treated in the 3-to 6-hour period, overall, and in the treatment-favorable and treatment-unfavorable subgroups. These results, shown in Figure 3 , were virtually identical in the derivation and test sets, suggesting good generalizability, and suggesting that the model might be especially useful for excluding patients who would be harmed by rt-PA.
Discussion
According to Stroke-TPI predictions, there is tremendous heterogeneity in the expected benefit for patients treated with rt-PA between 3 and 6 hours after stroke onset. When patients are classified as treatment-favorable versus treatmentunfavorable based on Stroke-TPI predictions, there is a dramatic divergence of treatment effects. Models developed on bootstrapped samples by automated procedures yielded somewhat less divergent treatment effects on average in treatment-favorable versus treatment-unfavorable patients (Figure 2 ). Yet even in the test datasets of these bootstrapped samples, the benefit seen among treatment-favorable patients represents an important improvement compared with the overall 3-to 6-hour group. These results are consistent with other recent studies emphasizing the need to look beyond the average treatment effect found in a randomized trial for therapies with significant risks and benefits. [12] [13] [14] In developing the Stroke-TPI, we identified 4 variables that diminish the benefits of rt-PA: longer symptom onset to treatment time, male sex, higher systolic blood pressure, and previous stroke. The Stroke-TPI's ability to select treatmentfavorable patients in an independent population depends on whether these associations with treatment effect arose by chance in this database, or whether they are true biologically based treatment modifiers. Longer symptom onset to treatment time is well-accepted to modify the treatment effects of thrombolytic therapy, based on clinical trials, 5, 15 as well as biologic plausibility, animal models of reperfusion 16 and by analogy with results in acute myocardial infarction (AMI). 17 There is ample evidence from independent data that higher systolic blood pressure is associated with an increased risk of thrombolytic-related intracranial hemorrhage in both AMI 18 -20 and stroke. [21] [22] [23] Previous stroke has also been shown in multiple studies to increase the risk of thrombolytic-related intracranial hemorrhage in AMI, 18, 20 and presumably would diminish the probability of a normal or near-normal outcome even in patients who do not have hemorrhagic complications of thrombolysis. That male sex would be associated with less benefit from thrombolytics was initially unexpected. However, after the report of the sex-bytreatment interaction in this database, 24 confirmatory findings from independent data have been published. 25, 26, 27 There are several limitations to our study. First, a much larger database would have allowed for a single independent test data set sufficient for reliable treatment effect estimates in treatment-favorable and treatment-unfavorable subgroups, without the need for bootstrap re-sampling. However, as we used a complete cross-validation method (ie, new variables selected at each iteration, not just new coefficients) and validated on data excluded from model development, our test set results provide an estimate of the degree of over-optimism in the Stroke-TPI performance. The performance of the models built during the automated procedure likely represents an underestimation of the "gain" expected when using the Stroke-TPI on independent data, because the variable-outcome relationships in these models were not individually checked against clinical reasoning, and results of all models, including those of dubious quality, were averaged. In particular, although the Stroke-TPI includes 4 robust treatment effect interactions on which risk-benefit profiling depend, 56 of the 250 bootstrapped models included Յ2 treatmenteffect interactions, including 23 that did not even include a treatment-by-time interaction. Additionally, ongoing trials (such as ECASS 3) should provide the opportunity for future independent testing.
The model we present was limited also by the variables collected commonly across trials. In particular, serum markers and perfusion-diffusion magnetic resonance imaging have shown some preliminary promise for risk-benefit profiling, but these data were not included in these trials.
Despite these limitations, the approach presented here could be of substantial use. In the context of a clinical trial, improving the margin of benefit from 1.8% to 5.2% would dramatically diminish the sample size required for an adequately powered clinical trial, from an infeasible Ͼ20 000 to a more feasible Ͻ3000 patients. (With an expected margin of benefit of 6.3%, Ϸ1000 patients would be required for each trial arm for 80% statistical power.) Use of such a model Notes: All models included treatment; 27 models included treatment, but no treatmentϫtime interaction; 3 models included treatment, treatmentϫtime, but no other treatment interactions; 26 models included treatmentϫtime and 1 other treatment interaction; 194 models included treatmentϫtime and at least 2 other treatment interactions.
DM indicates diabetes; SBP, systolic blood pressure; MABP, mean arterial blood pressure.
could also have an important effect in clinical care. In the ECASS I and II trials, Ϸ80% to 85% of patients were treated after 3 hours. Thus, using estimates from these enrollees, treating even two-thirds of this group of patients could more than triple the number of patients eligible for rt-PA (ie, from 20% of ECASS enrollees to Ͼ70%), although other studies suggest that the number of patients otherwise eligible for treatment in this time window may be less. 28 In summary, we have demonstrated that there is a great deal of heterogeneity in the treatment effect of rt-PA for acute stroke, and that the Stroke-TPI may be effective in identifying those patients most likely to benefit from treatment in the 3- Figure 2 . Normal or near-normal outcome in patients treated from 3 to 6 hours in the treatment-unfavorable and treatment-favorable subgroups (Derivation and Validation Datasets). This figure illustrates the proportion of patients with normal or near-normal outcomes (mRS Յ1) at 90 days in each of the treatment groups. These outcomes represent averages Ͼ250 modeling cycles. There was essentially no difference in the outcome between rt-PA-treated and control patients overall. However, treatment with rt-PA at this time in the subgroup with unfavorable characteristics (on average, 33% of the overall sample) appears to be harmful, whereas treatment with rt-PA in patients with favorable characteristics (on average 67% of the overall sample) appears to be beneficial. Comparison between the top and bottom panels demonstrates that the models' ability to discriminate on the basis of benefit was consistent but, on average, somewhat better in the derivation compared with the test set.
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